Merola, J.; Conrad, C.; Foley, P.; Iversen, L.; Langley, R.; Kokolakis, G.; Davis, L.; Hoepken, B.; Dixon, J.; Warren, R. Bimekizumab Versus Secukinumab Continuous Maintenance of PASI 90 and PASI 100 Responses through One Year in Patients With Moderate to Severe Plaque Psoriasis: Post-HOC Results from the BE RADIANT Phase 3b Trial. J of Skin 2024, 8, s403.